Lung cancer hypercalcemia with

Paraneoplastic syndromes commonly associated with lung cancers include cachexia, hypercalcemia, syndrome of inappropriate antidiuretic hormone secretion, and Cushing s syndrome. 

Calcitonin (Cibacalcin) a hormone, to a client with hypercalcemia from lung cancer. 

Hypercalcemia occurs in 10% to 30% of patients with cancer during the course of their disease. The most common tumor types associated with hypercalcemia are breast cancer squamous cell carcinomas of the head, neck, and lung and renal cancer. 

Hypercalcemia of malignancy is a common occurrence in solid tumors of the lung and breast as well as multiple myeloma and adult T-cell lymphoma/leukemia (26). The hypercalcemia associated with breast cancer is usually seen in late stages of the disease in patients with extensive bone metastases. In squamous cell carcinoma of the lung or kidney, however, hypercalcemia is not correlated with disease stage and is not necessarily associated with bone metastases. The hypercalcemia results from increased bone resorption, decreased bone formation and increased renal tubular calcium reabsorption. These findings suggest that some tumors may secrete humoral factors with PTH-like actions. 

In hospitalized patients, hypercalcemia of malignancy is the major cause of hypercalcemia (26,, , 54). In two separate studies, 9X of all cancer patients had hypercalcemia of malignancy (. 56). Hypercalcemia of malignancy is most common in solid tumors such as carcinomas of the lung, breast, kidney, pancreas and ovary, but also occurs with multiple myeloma and adult T-cell lymphoma/ leukemia. It has been estimated that there is approximately an equal distribution between humoral factors and metastatic bone tumors for causing hypercalcemia of malignancy (26,57,58). 

---